Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Iresearch Atlanta

Neither a doctor nor a teaching hospital

Research payments

$5,536,199

540 payments

Through program year 2025, Iresearch Atlanta is reported as receiving $5,536,199 in research payments, across 540 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $245,736 200
2024 Research $716,444 32
2023 Research $1,016,666 79
2022 Research $903,697 22
2021 Research $1,266,881 55
2020 Research $548,206 28
2019 Research $838,568 124

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $1,973,828 134 payments
  2. Merck Sharp & Dohme Corporation $1,105,537 15 payments
  3. Eisai Inc. $678,234 38 payments
  4. Boehringer Ingelheim International GmbH $568,668 201 payments
  5. H. Lundbeck A S $487,912 20 payments
  6. Teva Pharmaceuticals USA, Inc. $260,339 17 payments
  7. Novo Nordisk AS $222,555 31 payments
  8. Biogen, Inc. $140,909 5 payments
  9. Supernus Pharmaceuticals, Inc. $40,822 11 payments
  10. Sage Therapeutics, Inc. $18,350 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Pharmacokinetics, Safety and Tolerability of Cariprazine in Pediatric Patients With Autism Spectrum Disorder Ages 5-17 Yrs $1,166,696 15 payments
  2. A Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer s Disease $1,035,566 9 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $678,234 38 payments
  4. Study With Lu Af87908 in Healthy Participants and Participants With Alzheimer's Disease $307,052 17 payments
  5. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $281,399 53 payments
  6. A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea $246,360 7 payments
  7. Phase II DRF study of NR2B modulation in MDD $244,652 2 payments
  8. Pharmacokinetics, Safety and Tolerability of Cariprazine in Pediatric Patients With Autism Spectrum Disorder Ages 5-17 Yrs $241,218 19 payments
  9. Nn6535-4725 $222,555 31 payments
  10. Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $180,859 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record